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Antibodies against desmoglein proteins account for intraepidermal 
immunobullous disorders in the pemphigus family of diseases. 
Antibodies against desmoglein 3 are responsible for the blisters 
seen in patients with pemphigus vulgaris, whereas antibodies 
against desmoglein 1 lead to the more superficial separation seen 
in pemphigus foliaceus. Similar in both clinical and histologic 
features to pemphigus foliaceus (PF), an endemic form of the 
disease, fogo selvagem (FS) is found in high prevalence in certain 
regions of Brazil (Diaz et al., 1989). The endemic nature of the 
condition is thought to be precipitated by an immune response 
to an environmental antigen(s), currently not yet identified. This 
unique epidemiologic phenomenon provides researchers with an opportunity to study the differences between 
endemic and sporadic forms of this disease.
In this issue of the Journal, Diaz et al. (2008) studied early immunologic responses among patients with FS to 
determine whether the IgM response differs from that seen in patients with the sporadic disease. In a comprehensive 
assessment of immune responses, they evaluated sera from patients with FS in rural endemic and urban areas of Brazil, 
patients with PF in the United States and Japan, and control subjects in these locations. Detection of desmoglein 1 IgM 
varied, with the highest levels (58%) in FS patients in endemic regions and control subjects (>50%) from the same 
areas. The desmoglein 1 IgM response was considerably lower (12–18%) in FS patients from urban areas of Brazil 
and still lower in patients from the United States (10%) and Japan (0%). Less variability was found in IgG responses in 
patients, with markedly lower responses in control subjects, apart from control subjects from rural areas of Brazil. The 
investigators hypothesize that an environmental agent responsible for the development of FS may cause an early IgM 
response that predates clinical disease.
Through the following questions we will examine this paper in greater detail. For brief answers please refer to http://
network.nature.com/group/jidclub.
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QUESTIONS
1. What is the role of desmoglein 1 IgG in the development of PF and FS?
2. What is the role of desmoglein 1 IgM in FS?
3.  Although the investigators suggest that desmoglein 1 IgM is the earliest finding in patients destined to develop FS, do any 
other possible explanations explain the data?
4.  What is the significance of and the rationale for performing studies with and without calcium and glycosylated  
desmoglein 1?
5. What clinical implications may be drawn from this report?
6. What additional studies would be useful to test the investigators’ hypothesis?
